Given the fact that Lapatinib is a dual EGFR/HER2 inhibitor, we chose the HER2 overexpressing BC cell line, HCC-1954, and the EGFR overexpressing benign control cell line, MCF-10A, for further evaluation. This evidence concerns the gene ERBB2 and breast cancer.